Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25667872 | 0.78 | NQO2 (0.44) | NQO2PTPN11 | |
| SCHEMBL25677898 | 0.72 | NOS3 (0.33) | NOS3NOS2 | |
| SCHEMBL22349135 | 0.72 | — | — | |
| SCHEMBL17232508 | 0.69 | NOS3 (0.38) | NOS3NOS2 | |
| SCHEMBL19932128 | 0.65 | NOS3 (0.38) | NOS3NOS2 | |
| SCHEMBL19412656 | 0.65 | NOS2 (0.48) | NOS3NOS2 | |
| SCHEMBL25702523 | 0.64 | NOS2 (0.43) | SLC22A12NOS3NOS2 | |
| SCHEMBL11891675 | 0.64 | NOS3 (0.40) | NOS3NOS2 | |
| SCHEMBL18508626 | 0.63 | PSEN1 (0.43) | SLC22A12 | |
| SCHEMBL19003090 | 0.62 | SIRT1 (0.40) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | NQO2 362/4885SLC22A12 3622/4885PTPN11 1037/4885 |
| US-11377441-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | NQO2 362/4885SLC22A12 3622/4885PTPN11 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.